ESAs: Not a convicted felon but still a suspect

American Journal of Hematology

Volumn 83, Issue 11, 2008, Pages 880-881

  Katodritou, Eirini ^a   Verrou, Evgenia ^a   Zervas, Konstantinos ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; ERYTHROPOIETIN; HEMOGLOBIN; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ANEMIA; BONE MARROW; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG INDICATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MICROENVIRONMENT; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 55549136110     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21282     Document Type: Letter

References (10)

1. Ludwig H, Anderson K, Dammaco F, et al. ESAs not the culprit: More studies required. Am J Hematol 10.1002/ajh.21270.
2. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis- stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 2008;83:697-701.
3. Steensma DP. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol 2008;83:693-694.
4. Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 2007;18:1369-1375.
5. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood, in press.
6. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171-2177.
7. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008;112:2726-2732.
8. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;67:39-61.
9. Katodritou E, Terpos E, Zervas K, et al. Hypochromic erythrocytes (%): A reliable marker of recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with multiple myeloma and lymphoma. Ann Hematol 2007;86:369-376.
10. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniformresponse criteria for multiplemyeloma. Leukemia 2006;9:1467-1473.